In Bearbeitung

Bitte warten ...

Einstellungen

Einstellungen

Gehe zu Anmeldung

1. CA2641347 - INDAZOLE-HETEROARYL DERIVATIVES

Anmerkung: Text basiert auf automatischer optischer Zeichenerkennung (OCR). Verwenden Sie bitte aus rechtlichen Gründen die PDF-Version.

[ EN ]
CLAIMS:
1. Compound: 5-(3-Benzoylamino-1H-indazol-5-yl)furan-2-carboxylic acid, or a pharmaceutically usable salt, solvate, tautomer or stereoisomer thereof, or a mixture thereof in all ratios.
2. Compound: 5-{3-[(Thiophene-2-carbonyl)amino]-1H-indazol-5-yl}-furan-2-carboxylic acid, or a pharmaceutically usable salt, solvate, tautomer or stereoisomer thereof, or a mixture thereof in all ratios.
3. Compound: 5-[3-(3-Chlorobenzoylamino)-1H-indazol-5-yl]furan-2-carboxylic acid, or a pharmaceutically usable salt, solvate, tautomer or stereoisomer thereof, or a mixture thereof in all ratios.
4. Compound: 5-[3-(3-Bromobenzoylamino)-1H-indazol-5-yl]furan-2-carboxylic acid, or a pharmaceutically usable salt, solvate, tautomer or stereoisomer thereof, or a mixture thereof in all ratios.
5. Compound:
5-[3-(3-Fluorobenzoylamino)-1H-indazol-5-yl]furan-2-carboxylic acid, or a pharmaceutically usable salt, solvate, tautomer or stereoisomer thereof, or a mixture thereof in all ratios.
6. Compound: 5-[3-(3-Methylbenzoylamino)-1H-indazol-5-yl]furan-2-carboxylic acid, or a pharmaceutically usable salt, solvate, tautomer or stereoisomer thereof, or a mixture thereof in all ratios.
7. Compound: 5-[3-(3-Hydroxybenzoylamino)-1H-indazol-5-yl]furan-2-carboxylic acid, or a pharmaceutically usable salt, solvate, tautomer or stereoisomer thereof, or a mixture thereof in all ratios.
8. A pharmaceutical composition comprising at least one compound as defined in any one of claims 1 to 7, or a pharmaceutically usable salt,
solvate, tautomer or stereoisomer thereof, or a mixture thereof in all ratios, and excipients and/or adjuvants.
9. Use of a compound as defined in any one of claims 1 to 7, or a pharmaceutically usable salt, solvate, tautomer or stereoisomer thereof, or a mixture thereof in all ratios, for the preparation of a pharmaceutical composition for the treatment of diseases, wherein the disease is a proliferative disorder, or for the treatment or prevention of diabetes, obesity, metabolic syndrome, dyslipidaemia, systemic and pulmonary hypertonia, cardiovascular disease, renal disease, cancer, tumour cells, tumour metastases, coagulopathies, neuronal excitability, glaucoma, cataract, or bacterial infections, for use in fibrosis, for use in antiinfection therapy, for increasing learning ability and attention, for the treatment and prophylaxis of cell ageing and stress, or for the treatment of tinnitus.
10. Use according to claim 9, wherein the proliferative disorder is a cancer.
11. Use according to claim 10, wherein a checkpoint pathway in the cancer has been mutated or upregulated.
12. Use according to claim 11, wherein the compound is for administration in combination with an additional therapeutic agent.
13. Use according to claim 12, wherein the compound and the additional therapeutic agent are for administration through the same pharmaceutical composition.
14. Use according to claim 12 or 13, wherein the additional therapeutic agent is an anticancer agent.
15. Use according to claim 9, wherein the diabetes is diabetes mellitus, diabetic nephropathy, diabetic neuropathy, diabetic angiopathy or microangiopathy.
16. Use according to claim 9, wherein the cardiovascular disease is cardiac
fibrosis after myocardial infarction, cardiac hypertrophy, cardiac insufficiency or arteriosclerosis.
17. Use according to claim 9, wherein the renal disease is glomerulosclerosis, nephrosclerosis, nephritis, nephropathy or electrolyte excretion disorder.
18. Use according to claim 9, wherein the fibrosis or inflammatory process is liver cirrhosis, pulmonary fibrosis, fibrosing pancreatitis, rheumatism and arthroses, Crohn's disease, chronic bronchitis, radiation fibrosis, sclerodermatitis, cystic fibrosis, scarring or Alzheimer's disease.
19. A kit comprising (a) a compound as defined in any one of claims 1 to 7 or a pharmaceutically usable solvate or stereoisomer thereof, or a mixture thereof in all ratios; (b) a further active ingredient; and (c) instructions for use.